More recently, it has been shown that drugs targeting mitogen-activated protein kinase (MAPK) inhibit thyroid cancer cell proliferation in association with the upregulation of long-GILZ (L-GILZ; a variant of GILZ), which exhibits anti-oncogenic and antiproliferative activities [32]. This evidence concerns the gene WNK2 and thyroid gland carcinoma.